News

Treating refractory and metastatic lung cancer


 

AT THE ASCO ANNUAL MEETING 2013

CHICAGO Dr. Roy Herbst of Yale University discusses early results for MPDL3280A, a new PD-L1 antibody for the treatment of non-small cell lung cancer; he also gives his take on other exciting lung cancer data being presented at the annual meeting of the American Society of Clinical Oncology.

Recommended Reading

Marijuana habit not linked to lung cancer
MDedge Hematology and Oncology
FDA approves first EGFR mutation companion diagnostic test for NSCLC
MDedge Hematology and Oncology
Cardiorespiratory fitness predicts cancer risk, outcomes in men
MDedge Hematology and Oncology
PD-L1 blocker shrinks tumors with modest adverse events
MDedge Hematology and Oncology
Standard-dose radiation bests high-dose radiation in advanced NSCLC
MDedge Hematology and Oncology
Community Oncology Podcast: Bosutinib for CML and lung cancer management
MDedge Hematology and Oncology
Ultralow-dose CT bests X-Ray for lung cancer follow-up, but is it enough?
MDedge Hematology and Oncology
Real-world NLST results show CT scans find more early-stage lung cancers
MDedge Hematology and Oncology
CDC urges doctors to help patients quit smoking
MDedge Hematology and Oncology
Survival equivalent with sublobar, lobar resection of stage Ia NSCLC
MDedge Hematology and Oncology